KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
Erasca, Inc.
Tizona Therapeutics, Inc
GlaxoSmithKline
Bristol-Myers Squibb
Synthorx, Inc, a Sanofi company
Mirati Therapeutics Inc.
BioAtla, Inc.
Pfizer
Sanofi
Celgene
GlaxoSmithKline
Biond Biologics
Eisai Inc.
Nektar Therapeutics
NKGen Biotech, Inc.
Eli Lilly and Company
Bayer
Eli Lilly and Company
Novartis
Merck Sharp & Dohme LLC
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
AbbVie
Hoffmann-La Roche
Merck KGaA, Darmstadt, Germany
Hoffmann-La Roche
Hoffmann-La Roche
Eli Lilly and Company
Eli Lilly and Company
Regeneron Pharmaceuticals
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Eli Lilly and Company
Eli Lilly and Company
Harrison Clinical Research